EMEA-002954-PIP02-21
Key facts
| Active substance |
|
| Therapeutic area |
Vaccines
|
| Decision number |
P/0473/2021
|
| PIP number |
EMEA-002954-PIP02-21
|
| Pharmaceutical form(s) |
Suspension for injection
|
| Condition(s) / indication(s) |
Prevention of Meningococcal disease
|
| Route(s) of administration |
Intramuscular use
|
| Contact for public enquiries |
Sanofi Pasteur
|
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|